As part of our series focussing on medicines in Australia, we have added a product review of the use of clozapine for treatment-resistant schizophrenia and the risk of clozapine-induced gastrointestinal hypomotility.
This publication focuses on the pharmacological and clinical characteristics of clozapine for people with treatment-resistant schizophrenia and highlights clozapine-induced gastrointestinal hypomotility. It provides commentary from Professor Bruce Singh, Emeritus Professor of Psychiatry at the University of Melbourne.
Please login below to download this issue (PDF)